Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906421 · ClinicalTrials.gov registry record · Phase 2
Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Sagimet Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT04906421 is a Phase 2 study that has completed, run by Sagimet Biosciences. The registered enrollment target is 168 participants.
The verdict
NCT04906421, a Phase 2 study, has completed, sponsored by Sagimet Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH). Subjects will be randomly assigned toTVB-2640 or matching placebo PO QD for 52 weeks, with the first dose administered on Day 1.
Interventions
- OTHER Placebo
- DRUG TVB-2640
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2021-08-12 |
| Est. Completion | 2023-10-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04906421
The ClinicalTrials.gov registry entry for NCT04906421 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sagimet Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04906421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04906421 about?
NCT04906421 is a clinical study titled "Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)". This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH). Subjects will be randomly assigned toTVB-2640 or matching placebo PO QD for 52 weeks, with the first dose adminis...
What is the current status of trial NCT04906421?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2021-08-12. Estimated completion is 2023-10-02.
What interventions are being tested in trial NCT04906421?
The interventions under investigation include: Placebo (OTHER), TVB-2640 (DRUG).
Who is sponsoring clinical trial NCT04906421?
This trial is sponsored by Sagimet Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.